Comparative Pharmacology
Head-to-head clinical analysis: DOLUTEGRAVIR AND LAMIVUDINE versus EMTRICITABINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOLUTEGRAVIR AND LAMIVUDINE versus EMTRICITABINE.
DOLUTEGRAVIR AND LAMIVUDINE vs EMTRICITABINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that is phosphorylated to its active metabolite, which competes with endogenous deoxycytidine triphosphate for incorporation into viral DNA, leading to chain termination.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
One tablet (dolutegravir 50 mg/lamivudine 300 mg) orally once daily.
200 mg orally once daily, typically in combination with other antiretroviral agents.
None Documented
None Documented
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
Dolutegravir: ~14 hours (terminal). Lamivudine: ~13-19 hours (terminal). Both support once-daily dosing.
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Dolutegravir: ~53% excreted unchanged in feces via biliary secretion, ~31% in urine. Lamivudine: ~70% excreted unchanged in urine via glomerular filtration and active tubular secretion.
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Category A/B
Category C
NRTI
Antiretroviral, NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."